Session » (0283–0307) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 0287

6-Minute Walk Distance Associates with Physiologic Measures and Physician/Patient Reported Outcomes in Myositis Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 0298

Accuracy of the 2017 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) Classification Criteria and Myositis-Specific Autoantibodies-Based Classification Criteria for Classifying Patients with Idiopathic Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 0293

Characteristics and Outcomes of Idiopathic Inflammatory Myositis Associated Interstitial Lung Disease in Rural Appalachia

9:00AM-11:00AM: Abstract Number: 0297

Characteristics of Anti-MDA-5 Associated Dermatomyositis in Southern California with a Large Hispanic Population: Case Series

9:00AM-11:00AM: Abstract Number: 0292

Comparison of Cardiovascular Risk of Myositis Patients and the General Population

9:00AM-11:00AM: Abstract Number: 0303

Development of a Human Cytotoxic Myoinjury Model with CD8+ T Cells and Muscle Cells Differentiated from Human Induced Pluripotent Stem Cells

9:00AM-11:00AM: Abstract Number: 0296

Does Presence of Anti-SSa and Ro52 Influence the Progression of Interstitial Lung Disease (ILD) in Idiopathic Inflammatory Myopathies (IIM)

9:00AM-11:00AM: Abstract Number: 0306

Fitbit Is a Valid and Reliable Physical Activity Monitor in Idiopathic Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 0304

Incidence of Disease Flares Following COVID-19 Vaccination in a Diverse Idiopathic Inflammatory Myopathy Cohort

9:00AM-11:00AM: Abstract Number: 0301

Inflammatory Myopathies and Their Relationship with Cancer in a Colombian Cohort

9:00AM-11:00AM: Abstract Number: 0307

Long-term Prognosis and Recurrence in anti-MDA-5 Antibody-positive Dermatomyositis

9:00AM-11:00AM: Abstract Number: 0289

Markers of Endothelial Damage Are Elevated in Patients with Dermatomyositis Associated Interstitial Lung Disease and Associated with Low Paraoxonase-1 Activity

9:00AM-11:00AM: Abstract Number: 0291

Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics

9:00AM-11:00AM: Abstract Number: 0300

Nailfold Videocapillaroscopy in Idiopathic Inflammatory Myopathy Compared with Healthy Controls

9:00AM-11:00AM: Abstract Number: 0285

Patient Reported Physical Function, Mental Health, and Treatment Patterns in Dermatomyositis

9:00AM-11:00AM: Abstract Number: 0290

Patient-reported Quality of Life and Working Status Outcomes in Ambulatory Patients with Idiopathic Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 0284

Phenotyping Calcinosis: A Rare Manifestation of Rare Diseases

9:00AM-11:00AM: Abstract Number: 0295

Pneumocystis Jirovecii Pneumonia in Patients with Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 0305

Prevalence and Clinical Significance of anti-Ro52 Antibodies in Antisynthetase Syndrome

9:00AM-11:00AM: Abstract Number: 0288

Proinflammatory Bioactive Lipid Mediators (BLM) Are Associated with Worse Anti-Oxidant Function of High Density Lipoproteins (HDL) in Patients with Idiopathic Inflammatory Myopathies (IIM)

9:00AM-11:00AM: Abstract Number: 0286

Relationship Between High Resolution Computed Tomography(HRCT) Quantitative Scores and Physiological and Clinical Features in Antisynthetase Syndrome Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 0302

Remission in Anti-HMGCR Positive Immune-mediated Necrotizing Myopathy Without the Use of Glucocorticoids: A Multicentric Study of 24 Patients

9:00AM-11:00AM: Abstract Number: 0294

Tofacitinib Treatment in Rheumatoid Arthritis Is Associated with Increased Lower Limb Muscle Volume: The Rheumatoid Arthritis and Muscle (RAMUS) Study

9:00AM-11:00AM: Abstract Number: 0283

Transcriptomic Profiles in Muscle Biopsies from Systemic Sclerosis Patients with Different Autoantibodies

9:00AM-11:00AM: Abstract Number: 0299

Trends and Outcomes of Hospitalized Patients with Idiopathic Inflammatory Myopathy and Venous Thromboembolism: A Nationwide Inpatient Sample Analysis from US (2016-2019)

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].